Golimumab is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate (MTX), active psoriatic arthritis, and active ankylosing spondylitis with or without methotrexate or other non-biologic disease-modifying antirheumatic drug (DMARD).
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content